BioLink is a specialty pharmaceutical company focused on the development and commercialization of patented treatments to meet the needs of underserved patient populations.
BioLink builds on reformulations of “gold standards of care” to provide novel treatments eligible for approval using 505(b)(2) New Drug Applications.
Focus on enhancement of standard of care treatments for chronic diseases
Pipeline depth & breadth: 5 drugs; multiple indications
Speed to market: 1 – 5 years
Minimal clinical risk: Established safety & efficacy
Limited development cost: < $10 million per drug for 505(b)(2) candidates
Experienced drug development team
BioLink Management Team
Dr. Deanna Nelson, President
Mr. Keith Satisky, General Counsel
BioLink Advisory Team
Ms. Nancy Chew, Regulatory Affairs North America
Dr. J. Mitchell Jones, Casimir Jones, Patent Attorneys
Mr. George Conbeer, Business Affairs (L,M&A)
Mr. John Spitznagel, Jr., Pharmaceutical Affairs
BioLink’s Research Collaborators
Dr. Chad Stahl, North Carolina State University
Dr. Jack Odle, North Carolina State University
Dr. Keith Hruska, Washington University, St. Louis
Dr. Dennis Miller, Cornell University
Dr. David Driscoll, UMass Medical School
BioLink is a specialty pharmaceutical company focused on the development and commercialization of patented treatments... Learn more here...
Check out our informative resources:
Phosphate Binding Study
This study critically examines the efficacy of phosphate binding. Download our paper here...
Literature Review: Magnesium Inclusion in Phosphate Binding
What may be observed if calcium and magnesium are used in combination?
If you missed us at ASN, you can still download our conference presentation material.
Partner With Us
At BioLink, we are always looking for terrific partners for our suite of products and patented molecules who can help us effectively reach appropriate patients and the clinicians who treat them. If you have an interest in Phosveda or any other BioLink assets, please reach out to us at email@example.com or 919-678-9478.